Vape Regulation at a Crossroads: Will the FDA's Accelerated Authorization Push Mean Stricter or Looser Oversight?

The Big News: FDA Plans to Speed Up Authorizations

On September 23, 2026, the Wall Street Journal dropped a significant story: the Trump administration is preparing to smooth the way for more tobacco products — including flavored vapes — to legally enter the market by changing the rules to speed up the authorization process. The report, by Liz Essley Whyte and Laura Cooper, cites people familiar with the matter saying the FDA is expected to announce in coming days that it will revisit a 2021 rule that outlined requirements for new tobacco applications.

The agency is looking to add more flexibility for companies to get more products authorized, according to the report. One potential approach: simplifying requirements for scientific studies and speeding review times.

These changes matter most for newer tobacco products — vapes and nicotine pouches — that don't qualify for the simplified market pathway that exists for older products like cigarettes. Tobacco companies have complained for years that the FDA review process takes far longer than the roughly six months mandated by Congress, sometimes stretching into years.

The "Looser Regulation" Argument

Critics see the accelerated authorization push as a clear step toward weaker oversight. Here's their case:

Lowering the Evidentiary Bar

If the FDA simplifies requirements for scientific studies, it means products could reach the market with less evidence supporting their safety profile. That's not just a theoretical concern — it's a direct worry voiced by the person who helped write the current rules.

Reversing First-Term Policy

The direction represents a striking reversal from Trump's first term, when the FDA banned fruit-flavored vapes in an effort to curb teen use. Now, the same administration is pushing to make it easier for flavored products to get authorized. That's not a subtle shift — it's a 180-degree turn on the role of flavors in tobacco regulation.

The Makary Precedent

Former FDA Commissioner Marty Makary resigned under pressure after clashing with the White House over flavored tobacco products, the Journal reported. His departure — and the rapid pace of flavored product authorizations that followed — suggests the administration is willing to replace leaders who don't move fast enough on approvals.

The May Enforcement Guidance

In May 2026, the FDA issued guidance that allowed companies to sell most tobacco products legally after they've filed applications but before they've received a complete scientific review. Public health groups including the Campaign for Tobacco-Free Kids have sued over that guidance, arguing the FDA violated federal law by not giving the public a chance to comment on the change.

The "Stricter, Smarter Regulation" Argument

Supporters of the changes say this isn't deregulation — it's fixing a broken system. Here's their case:

Getting Products Into the Regulatory System

Right now, millions of vapers are using products that exist in a regulatory grey area — they haven't been denied authorization, but they haven't been approved either. Speeding up the PMTA process means more products get a clear legal status, and the FDA can more effectively police the ones that don't meet standards.

Enforcement Is Actually Ramping Up

Even as the authorization process speeds up, enforcement against illegal products — particularly counterfeit and unregulated disposable vapes from China — continues to intensify. The administration frames this as a two-pronged strategy: expand the legal market while cracking down on the illegal one.

Industry's Case: Legal Market Fights Illegal Market

Tobacco companies and some policy experts argue that a more vibrant legal market, with more flavors available, would help combat the flood of illegal Chinese vapes that they say are blatantly marketed to teens. Their logic: if adults can legally buy flavored products from regulated brands, they're less likely to patronize the unregulated market where youth access is uncontrolled.

Congress Mandated Six Months — We're Way Over

The six-month review timeline isn't some industry fantasy — it's what Congress wrote into law. For years, the FDA has missed that target by a wide margin. Fixing that isn't "loosening" regulation; it's making the agency live up to its statutory obligations.

The Two Sides, Side by Side

Bipartisan Pushback — It's Not Just Partisan

One notable dimension of this debate: criticism isn't coming from just one side of the aisle. The Wall Street Journal reports that lawmakers on both sides have objected to the FDA's recent approvals of more flavored tobacco products, including blueberry and mango.

Senator Collins is a Republican, which makes her criticism significant. On the Democratic side, senators like Dick Durbin, Elizabeth Warren, and Richard Blumenthal have been even more vocal. When both parties are raising red flags about the same policy, it suggests the issue is more complex than the typical partisan framing.

Meanwhile, the industry is pushing from the other direction. In September 2026, a group of manufacturers and retailers — including Altria-owned vape business NJOY — sued the FDA over the 2021 rule, saying the agency's "regulatory roadblocks" led to an "insurmountable logjam" of applications that has kept new products off the market.

The Industry Lawsuit: NJOY and the PMTA Logjam

The NJOY/Altria lawsuit is more than just one company's complaint — it's a window into broader industry frustration with the pace of PMTA reviews.

Here's what you need to know:

• The suit targets the 2021 rule that established PMTA scientific evidence standards
• Plaintiffs argue that FDA's slow processing has created an "insurmountable logjam"
• The WSJ reports that review times often take years, far exceeding Congress's six-month mandate
• The suit comes as the administration is already planning to revisit the 2021 rule — which could make some of the legal arguments moot, or could align with what the court ultimately orders

For context on what PMTA actually is and why it matters, check out our PMTA glossary breakdown of the process and its history.

State vs. Federal: The Fragmented Landscape

To understand whether regulation is getting looser or stricter, you can't just look at the federal level. State-level policy is moving in a different direction — and in many cases, state rules are more restrictive than federal ones.

This fragmentation means the answer to "is regulation getting looser or stricter?" depends heavily on where you live. In states with flavor bans, the legal market for flavored products is essentially zero — regardless of what the FDA does federally. In states without flavor bans, the accelerated federal process could meaningfully expand the legal flavored product market.

For a deeper look at the market implications of these regulatory shifts, see our analysis of top brands and disposable trends in the current environment.

Key Variable: The Heidi Overton Factor

None of this happens in a vacuum. The Wall Street Journal notes that flavored vapes are likely to be a "flashpoint" in Dr. Heidi Overton's FDA commissioner confirmation hearing — which took place on September 24.

Overton's policy direction on flavored products and PMTA processing speed will shape how the accelerated authorization plan actually gets implemented. If confirmed, she'll be the one overseeing the rule revisions, the review speed targets, and the enforcement priorities.

For a detailed look at Overton's background and what her confirmation could mean, see our full analysis of the new FDA commissioner and vaping's future.

The Dual-Track Theory: A Framework for Understanding What's Happening

After reviewing the evidence from both sides, here's a framework that we think better describes what's actually happening than either "looser" or "stricter" alone:

The dual-track system. Two processes are happening simultaneously, and they're pushing in different directions:

In this framework, "looser" and "stricter" are both partially right — they're just describing different tracks. The compliance track is loosening (in the sense of being faster and more accessible), while the enforcement track is tightening against products that stay outside the system.

The crucial question is whether both tracks actually work as intended. If the compliance track speeds up but the enforcement track doesn't deliver, the result is more products on the market with less scrutiny — the "looser" outcome. If both tracks work, the result is a larger but better-regulated legal market squeezing out the unregulated one — the "smarter" outcome.

What This Means for Different People

Frequently Asked Questions

Is the FDA loosening vape regulations?

The picture is more nuanced than simply 'loosening.' On one hand, the Trump administration plans to speed up PMTA authorizations by simplifying scientific study requirements and revisiting the 2021 rule. On the other hand, enforcement against illegal products continues, and state-level flavor bans are expanding. It's better described as a dual-track system: faster access for compliant products, faster removal for non-compliant ones.

What is the FDA's 2021 PMTA rule?

The 2021 PMTA rule established the scientific evidence standards that companies must meet to have new tobacco products authorized for sale in the U.S. The Wall Street Journal reported on September 23, 2026, that the FDA plans to revisit this rule to add more flexibility and potentially speed up review times.

Why is NJOY suing the FDA?

In September 2026, a group of manufacturers and retailers including Altria-owned NJOY sued the FDA over the 2021 PMTA rule, arguing that the agency's 'regulatory roadblocks' created an 'insurmountable logjam' of applications that has kept new products off the market. They point to review times far exceeding the congressionally mandated six-month timeline.

What does Mitch Zeller say about accelerated approvals?

Mitch Zeller, former director of FDA's Center for Tobacco Products who helped write the 2021 rule, expressed skepticism. As quoted in the Wall Street Journal on September 23, 2026: 'The solution to the massive problem of illicit flavored vapes today is the right kind of enforcement action, not new policy that lowers the evidentiary bar to get more flavored products authorized.'

How long does PMTA review take?

Congress mandated a review period of approximately six months for PMTA applications. In practice, reviews have taken significantly longer — sometimes years. Tobacco companies have long complained about these delays, and the FDA reduced its PMTA backlog by roughly 70% in 2025 but still faces ongoing criticism about processing speed.

What states have banned flavored vapes?

As of September 2026, states with comprehensive flavor bans include California, New York, New Jersey, Rhode Island, and Washington, DC. Some states, like New York, have exceptions for products that have received FDA premarket approval. The landscape continues to evolve as more states consider flavor restrictions.

Will accelerated approval bring more flavored vapes to market?

The stated goal of the Trump administration's plan is to make it easier for products considered less harmful for smokers, including flavored vapes, to enter the market legally. However, several factors could limit this: legal challenges from public health groups, state-level flavor bans, and the requirement that products still must meet public health standards. The net effect depends on how these factors balance out.

What is the dual-track regulatory system?

The 'dual-track' theory describes a regulatory environment where two processes happen simultaneously: (1) compliant products move through authorization faster and enter the legal market, and (2) enforcement against illegal, unregulated products intensifies. The result would be a market where legal, regulated products expand while grey-market products shrink.

We Want to Hear From You

Where do you land on the "looser vs. smarter" debate? We want to know what you think:

• Do you see the FDA's accelerated authorization plan as deregulation or as fixing a broken process?
• Has your state changed its vape laws recently? How has it affected you?
• Do you trust that faster reviews can happen without sacrificing safety standards?
• What's the single most important thing the FDA should get right in the revised 2021 rule?

Quick poll: Five years from now, how do you think vaping regulation in America will compare to today?

1. Much looser — far more products available legally
2. Somewhat looser but better enforced
3. About the same — just more of the same
4. Stricter — fewer products, stronger enforcement

Cast your vote and share your reasoning. We read every comment.

Sources & Further Reading

1. Essley Whyte, L. & Cooper, L. (2026, September 23). "U.S. Regulators Plan Major Move to Speed Authorizations of Vapes, Tobacco Pouches." The Wall Street Journal. — WSJ.com
2. U.S. Food and Drug Administration. "Premarket Tobacco Product Applications." FDA Tobacco Products. — fda.gov
3. U.S. Food and Drug Administration. "Enforcement Priorities for Tobacco Products." FDA Tobacco Products. — fda.gov
4. Campaign for Tobacco-Free Kids. (2026). Lawsuit challenging FDA May 2026 enforcement guidance. — tobaccofreekids.org
5. Durbin, D. (2026). "Durbin Urges HHS Secretary Kennedy to Intervene and Push Back on FDA Allowing Flavored Vapes That Harm Our Children." Senator Durbin Press Office. — durbin.senate.gov
6. U.S. Senate HELP Committee. (2026). "Nomination of Heidi Overton to be Commissioner of Food and Drugs." — help.senate.gov
7. CBS News. (2026, May 12). "Marty Makary out as FDA commissioner." — cbsnews.com
8. Truth Initiative. (2025). "Flavored Tobacco Sales Restrictions Q2 2025." — truthinitiative.org
9. NJOY / Altria. (2026, September). Lawsuit against FDA over PMTA rule. — altria.com
10. U.S. Food and Drug Administration. (2026, August 28). "FDA authorizes JUUL2 electronic nicotine delivery system." — fda.gov